Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of...

Celý popis

Podrobná bibliografie

Vydáno v:	Expert opinion on investigational drugs Ročník 9; číslo 12; s. 2903 - 2911
Hlavní autor:	Kelland, Lloyd R
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Ashley Publications Ltd 01.12.2000 Taylor & Francis
Témata:	Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use cancer Clinical Trials as Topic cyclin-dependent kinase Cyclin-Dependent Kinases - antagonists & inhibitors Flavonoids - pharmacology Flavonoids - therapeutic use flavopiridol Humans inhibitor Neoplasms - drug therapy Piperidines - pharmacology Piperidines - therapeutic use
ISSN:	1354-3784, 1744-7658
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!